Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 65   

Articles published

ARNA 4.17 -0.01 (-0.24%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the ...
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Arena Pharmaceuticals APD811 Pipeline Advancement The First Of Several ...
Shares of Arena Pharmaceuticals (NASDAQ:ARNA) have been consolidating in an ever tighter range since the June 27th approval of their obesity drug BELVIQ.
Related articles »  
Arena Pharma (ARNA), Vivus (VVUS): Which Hedge Funds Made the Wrong ...
Since the end of 2Q, the very popular biopharma companies, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and Vivus, Inc. (NASDAQ:VVUS) have performed poorly.
Can Orexigan Benefit From Possible FDA Changes In Approval?  Seeking Alpha
Related articles »  
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
Now Could Be The Time To Speculate On Achillion Pharmaceuticals
That will cost Achillion a large percentage of all future profits (still not an awful deal at this point), just as Arena had to do.
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
Related articles »  
FDA Considers Faster Approval Process for Obesity Drugs
Arena Pharmaceuticals Inc. (ARNA:US)'s Belviq weight-loss pill and Vivus Inc. (VVUS:US)'s Qsymia may have been approved earlier for use by morbidly obese people had such a path existed.
Related articles »  
Eisai's Epilepsy Drug Helps Obese Patients Reduce Weight
The efficacy was similar to Roche Holding AG (ROG)'s Xenical and Arena Pharmaceuticals Inc. (ARNA:US)'s Belviq. Side effects such as mood changes and memory problems occurred more frequently than with a placebo, the authors of the study at Duke ...
Related articles »  
3 Best Biotech Stocks For This Week (Part VII)
... symptomatic neurogenic orthostatic hypotension. So in this article, I will write about the reasons to take a speculative position in Cell Therapeutics Inc (NASDAQ:CTIC), Arena Pharmaceuticals (NASDAQ:ARNA) and Chelsea Therapeutics (NASDAQ:CHTP).
IPOs, FDA Approvals, and M&A Revive the Biotechnology Industry
... prostate cancer; Onyx Pharmaceuticals (NASDAQ:ONXX) for Kyprolis that treats a rare blood cancer; VIVUS Inc. (NASDAQ:VVUS) for Qsymia (TM) for the treatment of obesity; Arena Pharmaceuticals (NASDAQ:ARNA) for Lorcaserin that also treats obesity; ...
Related articles »